Bio-Path Holdings (NASDAQ:BPTH) has announced that it has received a notice of allowance from the US Patent and Trademark Office for prexigerbersen (BP1001). The company develops nucleic cancer treatments through its DNAbilize® liposomal delivery and antisense tech.
Bio-Path receives new patent for prexigerbersen
The notice is for claims associated with prexigebersen, its lead product candidate. This is in combination with cytidine analogues like decitabine or Bcr-Abl tyrosine kinase inhibitors nilotinib and dasatinib. Prexigebersen is a liposomal formulation that contains antisense oligodeoxynucleotide that targets growth factor receptor-bound protein 2 (Grb2).
The new patent based on Application no 16/33,221 is titled “Combination Therapy with Liposomal Antisense Oligonucleotides.” The patent will offer broad protection for the application of prexigerbersen in combination with standard of care therapies in treating various forms of cancer. Peter Nielsen, the CEO and President of Bio-path, said that the patent will strengthen its intellectual property portfolio and complement the already issued patents.
Nielsen said that their growing list of patents has become a valuable asset for the company. This is because it offers protection to Bio-path’s research efforts and main product portfolio and offers protection in combination with various standard of care therapies. The company is currently conducting Phase 2 clinical trials for prexigerbersen combined with decitabine in treating acute myeloid leukemia.
New patent protects research initiatives in developing AML treatment
Nielsen added that the new patent offers protection to the unique therapy combination. It also supports continuing investment in the program to deliver a new treatment alternative for AML patients with limited treatment alternatives.
Through its proprietary DNAbilize® technology, the company has developed a range of RNAi nanoparticle drugs that can be intravenously administered. Prexigerbersen (BP1001) is a treatment that targets Grb2 protein and is currently in Phase 2 trials for blood cancers. BP1001 is under FDA consideration for the commencement of Phase 1 studies in the treatment of solid tumors. Besides BP1001, the company’s BP1002 targets BCl-2 protein, and it is currently being studied in the treatment of chronic lymphocytic leukemia and lymphoma.